<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04865107</url>
  </required_header>
  <id_info>
    <org_study_id>CIRCA-19 RCT</org_study_id>
    <nct_id>NCT04865107</nct_id>
  </id_info>
  <brief_title>Cellular Immuno-Therapy for COVID-19 ARDS Randomized Clinical Trial</brief_title>
  <acronym>CIRCA-19 RCT</acronym>
  <official_title>Cellular Immuno-Therapy for COVID-19 ARDS Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 multicenter randomized (2:1), placebo-controlled trial to evaluate early&#xD;
      signs of efficacy of allogeneic, umbilical cord-derived (UC) mesenchymal stromal cells (MSCs)&#xD;
      in patients with COVID-19 and Acute Respiratory Distress Syndrome (ARDS).&#xD;
&#xD;
      Randomized participants (N=54) will receive 3 daily doses of up to 90-million cells/unit dose&#xD;
      (cumulative dose of up to 270 million UC-MSCs) or blinded placebo. The MSC product will be&#xD;
      provided as 2.5 million cells/ml suspended in PlasmaLyte A containing 5% Human Albumin. The&#xD;
      appearance-matched placebo product contains the same excipients, PlasmaLyte A and 5% Human&#xD;
      Albumin, as the UC-MSCs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized (2:1) placebo-controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days free of oxygen by NIV/HFNC or mechanical ventilation at Day 28</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of systemic inflammatory response</measure>
    <time_frame>Change from Baseline to 24 hours after each MSC infusion</time_frame>
    <description>Interleukin levels change from Baseline to 24 hours after each MSC infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of endothelial function</measure>
    <time_frame>Change from Baseline to 24 hours after each MSC infusion</time_frame>
    <description>Angiopoietin levels change from Baseline to 24 hours after each MSC infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>Day 28</time_frame>
    <description>Number of deaths at day 28</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety events (SAEs, AEs)</measure>
    <time_frame>At time of infusion until one year post-infusion</time_frame>
    <description>allergic reactions, infusion related reactions, and venous and arterial thrombotic events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Covid19</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>MSCs Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UC-MSCs</intervention_name>
    <description>3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)</description>
    <arm_group_label>MSCs Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PlasmaLyte A and 5% Human Albumin</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of ≥18 years&#xD;
&#xD;
          -  Laboratory-confirmed SARS-CoV-2 infection during the current admission&#xD;
&#xD;
          -  On invasive, non-invasive mechanical ventilation (NIV) (PEEP ≥5 cmH20) or high-flow&#xD;
             nasal canula (HFNC) oxygen therapy (minimum total flow rate of 40 lpm)&#xD;
&#xD;
          -  ARDS (onset &lt;96h) as per the international consensus definition (P/F ratio &lt; 300 with&#xD;
             PEEP ≥5cm H20 or on HFNC), not due primarily to cardiac causes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No consent/inability to obtain consent&#xD;
&#xD;
          -  Rockwood Clinical Frailty Score &gt; 4&#xD;
&#xD;
          -  Moribund patient not expected to survive 24 hours&#xD;
&#xD;
          -  Any other irreversible disease or condition for which 6-month mortality is estimated&#xD;
             to be greater than 50%&#xD;
&#xD;
          -  Currently receiving extracorporeal life support&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Patients with a prior or concurrent malignancy whose natural history or treatment does&#xD;
             not have the potential to interfere with the safety or efficacy assessment of the&#xD;
             investigational regimen are eligible for this trial&#xD;
&#xD;
          -  Moderate to severe chronic liver disease (Childs-Pugh Score &gt; 12)&#xD;
&#xD;
          -  Severe chronic respiratory disease with a baseline PaCO2 &gt; 50 mm Hg or the use of home&#xD;
             oxygen&#xD;
&#xD;
          -  Documented deep venous thrombosis or pulmonary embolism within the preceding 3 months&#xD;
&#xD;
          -  Inability/contra-indications to receiving local standard of care thromboprophylaxis&#xD;
&#xD;
          -  Chronic immunosuppression (any chronic immunotherapy including daily oral steroid use&#xD;
             &gt;6months)&#xD;
&#xD;
          -  Known HIV, Hep B/C positive, or active tuberculosis&#xD;
&#xD;
          -  Multisystem shock (SOFA score change from baseline of &gt;2 in &gt;2 systems)&#xD;
&#xD;
          -  Patient, surrogate, or physician not committed to full support including intubation&#xD;
             (exception: a patient will not be excluded if he/she would receive all supportive care&#xD;
             except for attempts at resuscitation from cardiac arrest)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duncan J Stewart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ottawa Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Duncan J Stewart, MD</last_name>
    <phone>613-798-5555</phone>
    <phone_ext>7917</phone_ext>
    <email>djstewart@ohri.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lakeridge Health</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>ON L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Soliman, MD</last_name>
      <email>ksoliman@lh.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duncan J Stewart, MD</last_name>
      <phone>+1 613-737-8899</phone>
      <phone_ext>75083</phone_ext>
      <email>djstewart@toh.ca</email>
    </contact>
    <investigator>
      <last_name>Shane English, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dean Fergusson, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manoj Lalu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard Thebaud, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Courtman, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Dos Santos, MD</last_name>
      <email>Claudia.DosSantos@unityhealth.to</email>
    </contact>
    <investigator>
      <last_name>Kim Connelly, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michaël Chassé, MD</last_name>
      <email>michael.chasse@umontreal.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

